Market Research Report
Breast Cancer Diagnostic and Drug Technologies: Global Markets
|Published by||BCC Research||Product code||245536|
|Published||Content info||150 Pages
Delivery time: 1-2 business days
|Breast Cancer Diagnostic and Drug Technologies: Global Markets|
|Published: November 28, 2019||Content info: 150 Pages||
The global breast cancer diagnostic and drug market should reach $28.2 billion by 2024 from $20.9 billion in 2019 at a compound annual growth rate (CAGR) of 6.2% for the forecast period of 2019 to 2024.
The drug technology segment of the global breast cancer diagnostic and drug market is expected to grow from $17.9 billion in 2019 to $23.7 billion in 2024 at a CAGR of 5.8% for the forecast period of 2019 to 2024.
The companion diagnostics segment of the global breast cancer diagnostic and drug market is expected to grow from $418.2 billion in 2019 to $1.1 billion in 2024 at a CAGR of 21.4% for the forecast period of 2019 to 2024.
This report is an update to Breast Cancer Diagnostics and Therapeutics Market Report-HLC106B.
The objective of the current report is to provide readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic developments.
This report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates, the regulatory environment for markers and therapeutics, recent regulatory approvals, current and new technologies, market projections and the market share of key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.
This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.
This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2018 (the base year), 2019 and a forecast for 2024.